Table III.
Exp | Genotype | Percent viability |
Cells/ml × 10−6 |
Percent IgG+ cells |
[IgG1] | [IgE] |
---|---|---|---|---|---|---|
ng/ml | ng/ml | |||||
A | s/+ | 73 | 2.2 | 18.0 | 242 | 8 |
tg s/+ | 76 | 2.2 | 10.1 | 85 | <1 | |
tg s/s | 58 | 2.1 | 9.2 | 97 | <1 | |
tg s/s | 52 | 2.5 | 10.0 | 108 | <1 | |
B | s/+ | 77 | 1.8 | 12.6 | 723 | 48 |
tg s/+ | 68 | 1.7 | 10.2 | 587 | 20 | |
tg s/s | 78 | 1.1 | 7.7 | 312 | <1 | |
tg s/s | 62 | 1.8 | 8.9 | 305 | <1 |
Spleen cells from individual 3H9sdVk8sd scid mice (tg s/s) and sorted B220+ splenic cells from a 3H9sdVκ8 scid/+ (tg s/+) and nontransgenic scid/+ (s/+) control mouse were plated at 0.25 × 106 cells/ml. The source of cells for each genotype shown was an individual mouse. (A and B represent additional, independent experiments to those described in Fig. 7 A). Cell counts were made as described in Table I. The percentage of IgG1+ cells and levels of secreted IgG1 and IgE were ascertained by flow cytometry and ELISA, respectively (Materials and Methods).